Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
J Med Biochem
This highlights the complexity of GPCR activation, where downstream signalling is influenced by the interplay of multiple transducers that can interact with activated receptors (pleiotropic coupling), and can also be influenced by different trafficking profiles that alter the location of the receptor in the cell
Similarly, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model, GLP-1 analogues were reported to protect the brain from MPTP-induced pathological effects, such as movement disorders, increased levels of -synuclein, chronic inflammation in the brain, loss of dopaminergic neurons, oxidative stress, and expression of growth factors (65)
Pricing is transparent, with no hidden fees
Oral Non-Peptide GLP-1 Receptor Agonist Market Report Scope: Market Segmentation: Oral Non-Peptide GLP-1 Receptor Agonist Market by Type- Small Molecule GLP-1 Agonists Peptide-Based Oral Formulations Combination GLP-1 Therapies Oral Non-Peptide GLP-1 Receptor Agonist Market by Application- Obesity & Weight Management Type 2 Diabetes Cardiovascular Risk Reduction Non-Alcoholic Steatohepatitis (NASH) Oral Non-Peptide GLP-1 Receptor Agonist Market by Distribution Channel - Retail Pharmacy Telehealth & Direct-to-Patient Hospital & Clinic Research Design and Approach This study employed a multi-step, mixed-method research approach that integrates: Secondary research Primary research Data triangulation Hybrid top-down and bottom-up modelling Forecasting and scenario analysis This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market
Use the formula
